Literature DB >> 24992837

Radiosensitisation by pharmacological ascorbate in glioblastoma multiforme cells, human glial cells, and HUVECs depends on their antioxidant and DNA repair capabilities and is not cancer specific.

M Leticia Castro1, Melanie J McConnell1, Patries M Herst2.   

Abstract

We previously showed that 5 mM ascorbate radiosensitized early passage radioresistant glioblastoma multiforme (GBM) cells derived from one patient tumor. Here we investigate the sensitivity of a panel of cell lines to 5 mM ascorbate and 6 Gy ionizing radiation, made up of three primary human GBM cells, three GBM cell lines, a human glial cell line, and primary human vascular endothelial cells. The response of different cells lines to ascorbate and/or radiation was determined by measuring viability, colony-forming ability, generation and repair of double-stranded DNA breaks (DSBs), cell cycle progression, antioxidant capacity and generation of reactive oxygen species. Individually, radiation and ascorbate both decreased viability and clonogenicity by inducing DNA damage, but had differential effects on cell cycle progression. Radiation led to G2/M arrest in most cells whereas ascorbate caused accumulation in S phase, which was moderately associated with poor DSB repair. While high dose ascorbate radiosensitized all cell lines in clonogenic assays, the sensitivity to radiation, high dose ascorbate, and combined treatment varied between cell lines. Normal glial cells were similar to GBM cells with respect to free radical scavenging potential and effect of treatment on DNA damage and repair, viability, and clonogenicity. Both GBM cells and normal cells coped equally poorly with oxidative stress caused by radiation and/or high dose ascorbate, dependent primarily on their antioxidant and DSB repair capacity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antioxidant capacity; Cell cycle arrest; DNA repair; Glioblastoma multiforme; High dose ascorbate; Radiation

Mesh:

Substances:

Year:  2014        PMID: 24992837     DOI: 10.1016/j.freeradbiomed.2014.06.022

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  17 in total

1.  Pharmacological Ascorbate as an Adjuvant for Enhancing Radiation-Chemotherapy Responses in Gastric Adenocarcinoma.

Authors:  Brianne R O'Leary; Frederick K Houwen; Chase L Johnson; Bryan G Allen; James J Mezhir; Daniel J Berg; Joseph J Cullen; Douglas R Spitz
Journal:  Radiat Res       Date:  2018-03-16       Impact factor: 2.841

2.  Calculated cell-specific intracellular hydrogen peroxide concentration: Relevance in cancer cell susceptibility during ascorbate therapy.

Authors:  Dieanira Erudaitius; Jacqueline Mantooth; Andrew Huang; Jesse Soliman; Claire M Doskey; Garry R Buettner; Victor G J Rodgers
Journal:  Free Radic Biol Med       Date:  2018-03-27       Impact factor: 7.376

3.  Clinical Targeting of Altered Metabolism in High-Grade Glioma.

Authors:  Andrew J Scott; Costas A Lyssiotis; Daniel R Wahl
Journal:  Cancer J       Date:  2021 Sep-Oct 01       Impact factor: 3.360

4.  Pharmacological doses of daily ascorbate protect tumors from radiation damage after a single dose of radiation in an intracranial mouse glioma model.

Authors:  Carole Grasso; Marie-Sophie Fabre; Sarah V Collis; M Leticia Castro; Cameron S Field; Nanette Schleich; Melanie J McConnell; Patries M Herst
Journal:  Front Oncol       Date:  2014-12-15       Impact factor: 6.244

Review 5.  Micronutrients in Oncological Intervention.

Authors:  Uwe Gröber; Peter Holzhauer; Klaus Kisters; Michael F Holick; Irenäus A Adamietz
Journal:  Nutrients       Date:  2016-03-12       Impact factor: 5.717

6.  Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy.

Authors:  Claire M Doskey; Visarut Buranasudja; Brett A Wagner; Justin G Wilkes; Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Redox Biol       Date:  2016-10-28       Impact factor: 11.799

7.  Peroxiporin Expression Is an Important Factor for Cancer Cell Susceptibility to Therapeutic H2O2: Implications for Pharmacological Ascorbate Therapy.

Authors:  Dieanira Erudaitius; Andrew Huang; Sarah Kazmi; Garry R Buettner; Victor G J Rodgers
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

8.  Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation.

Authors:  Yun-Xin Lu; Qi-Nian Wu; Dong-Liang Chen; Le-Zong Chen; Zi-Xian Wang; Chao Ren; Hai-Yu Mo; Ya Chen; Hui Sheng; Ying-Nan Wang; Yun Wang; Jia-Huan Lu; De-Shen Wang; Zhao-Lei Zeng; Feng Wang; Feng-Hua Wang; Yu-Hong Li; Huai-Qiang Ju; Rui-Hua Xu
Journal:  Theranostics       Date:  2018-02-02       Impact factor: 11.556

9.  High Dose Ascorbate Causes Both Genotoxic and Metabolic Stress in Glioma Cells.

Authors:  Maria Leticia Castro; Georgia M Carson; Melanie J McConnell; Patries M Herst
Journal:  Antioxidants (Basel)       Date:  2017-07-22

10.  High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study.

Authors:  Kishore Polireddy; Ruochen Dong; Gregory Reed; Jun Yu; Ping Chen; Stephen Williamson; Pierre-Christian Violet; Ziyan Pessetto; Andrew K Godwin; Fang Fan; Mark Levine; Jeanne A Drisko; Qi Chen
Journal:  Sci Rep       Date:  2017-12-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.